Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2018 Congress

ESMO 2018

Find all medweireNews articles about results presented during the congress.

Trifluridine–Tipiracil Improves Metastatic Gastric Cancer OS

A cytotoxic agent that combines trifluridine and tipiracil could be an option for the third- or later-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

Cisplatin Superior To Cetuximab For Low-Risk, HPV-Positive Oropharyngeal Cancer

For patients undergoing radiotherapy for low-risk, human papillomavirus-positive oropharyngeal cancer, cisplatin should remain the standard of care...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.